A detailed history of Vanguard Group Inc transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,715,554 shares of STOK stock, worth $23.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,715,554
Previous 1,648,502 4.07%
Holding current value
$23.2 Million
Previous $8.67 Million 167.09%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$4.12 - $14.17 $276,254 - $950,126
67,052 Added 4.07%
1,715,554 $23.2 Million
Q4 2023

Feb 14, 2024

BUY
$3.37 - $5.4 $60,033 - $96,195
17,814 Added 1.09%
1,648,502 $8.67 Million
Q3 2023

Nov 14, 2023

BUY
$3.78 - $11.99 $90,357 - $286,608
23,904 Added 1.49%
1,630,688 $6.42 Million
Q2 2023

Aug 14, 2023

BUY
$7.93 - $13.82 $3.77 Million - $6.56 Million
474,797 Added 41.94%
1,606,784 $17.1 Million
Q1 2023

May 15, 2023

SELL
$7.65 - $10.38 $3.6 Million - $4.88 Million
-470,058 Reduced 29.34%
1,131,987 $9.43 Million
Q4 2022

Feb 10, 2023

SELL
$7.07 - $15.69 $3.15 Million - $7 Million
-445,859 Reduced 21.77%
1,602,045 $14.8 Million
Q3 2022

Nov 14, 2022

BUY
$12.56 - $22.53 $664,059 - $1.19 Million
52,871 Added 2.65%
2,047,904 $26.3 Million
Q2 2022

Aug 12, 2022

BUY
$10.36 - $23.93 $576,461 - $1.33 Million
55,643 Added 2.87%
1,995,033 $26.4 Million
Q1 2022

May 13, 2022

BUY
$17.19 - $26.1 $467,705 - $710,128
27,208 Added 1.42%
1,939,390 $40.8 Million
Q4 2021

Feb 14, 2022

BUY
$18.11 - $30.72 $1.17 Million - $1.98 Million
64,567 Added 3.49%
1,912,182 $45.9 Million
Q3 2021

Nov 12, 2021

BUY
$23.65 - $34.44 $2.57 Million - $3.75 Million
108,813 Added 6.26%
1,847,615 $47 Million
Q2 2021

Aug 13, 2021

BUY
$30.53 - $41.09 $53.1 Million - $71.4 Million
1,738,802 New
1,738,802 $58.5 Million

Others Institutions Holding STOK

About Stoke Therapeutics, Inc.


  • Ticker STOK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,419,300
  • Market Cap $533M
  • Description
  • Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...
More about STOK
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.